Actively Recruiting
Efficacy and Safety Study of Mocravimod as Additional and Maintenance Treatment in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation
Led by Priothera SAS · Updated on 2026-10-30
366
Participants Needed
111
Research Sites
130 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the use of mocravimod as an additional and maintenance treatment for adults with acute myeloid leukemia AML who are undergoing allogeneic hematopoietic cell transplantation HCT. This phase III, multi-center, randomized, double-blind, placebo-controlled trial aims to assess the drugs safety and effectiveness in this patient population, focusing on improving relapse-free survival. Participants will be randomly assigned to one of three groups receiving 3 mg of mocravimod daily, 1 mg of mocravimod daily, or a placebo daily, all administered orally for 12 months. The study involves parallel groups and maintains quadruple masking to ensure unbiased results. During the trial, participants will be closely monitored with regular assessments to evaluate relapse-free survival over 12 months and overall survival over 24 months. Safety and efficacy will be observed throughout, with participants undergoing standard care alongside study treatments. The total participation duration aligns with the treatment and follow-up periods extending up to two years.
CONDITIONS
Brief Title
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Research Team
M
Malika Souquieres, MSc
J
Jens Hasskarl, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here